BR112018009528A2 - método para determinar o risco de recorrência de um câncer de mama de um sujeito, método para prever a capacidade de resposta a uma terapia de um câncer de mama de um sujeito, métodos ou tratamentos de um sujeito que tem câncer de mama que não foi tratado ou foi tratado com quimioterapia por 5 anos, métodos para recomendar o tratamento para um sujeito que tem câncer de mama, método para tratar um sujeito que tem câncer de mama - Google Patents
método para determinar o risco de recorrência de um câncer de mama de um sujeito, método para prever a capacidade de resposta a uma terapia de um câncer de mama de um sujeito, métodos ou tratamentos de um sujeito que tem câncer de mama que não foi tratado ou foi tratado com quimioterapia por 5 anos, métodos para recomendar o tratamento para um sujeito que tem câncer de mama, método para tratar um sujeito que tem câncer de mamaInfo
- Publication number
- BR112018009528A2 BR112018009528A2 BR112018009528A BR112018009528A BR112018009528A2 BR 112018009528 A2 BR112018009528 A2 BR 112018009528A2 BR 112018009528 A BR112018009528 A BR 112018009528A BR 112018009528 A BR112018009528 A BR 112018009528A BR 112018009528 A2 BR112018009528 A2 BR 112018009528A2
- Authority
- BR
- Brazil
- Prior art keywords
- subject
- breast cancer
- methods
- treated
- recurrence
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 10
- 206010006187 Breast cancer Diseases 0.000 title abstract 9
- 208000026310 Breast neoplasm Diseases 0.000 title abstract 9
- 238000011282 treatment Methods 0.000 title abstract 3
- 230000004043 responsiveness Effects 0.000 title abstract 2
- 238000002560 therapeutic procedure Methods 0.000 title abstract 2
- 238000002512 chemotherapy Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring And Recording Apparatus For Diagnosis (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
são apresentados métodos de determinação do risco da recorrência de um câncer de mama de um sujeito. também são fornecidos métodos para prever a capacidade de resposta a uma terapia de um câncer de mama de um sujeito. além disso, métodos de recomendação de tratamento para um sujeito com câncer de mama são fornecidos. além disso, são fornecidos métodos de tratamento de um sujeito que tem câncer de mama. sistemas para executar métodos descritos também são fornecidos.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562255260P | 2015-11-13 | 2015-11-13 | |
| US201562265964P | 2015-12-10 | 2015-12-10 | |
| PCT/US2016/061568 WO2017083675A1 (en) | 2015-11-13 | 2016-11-11 | Integration of tumor characteristics with breast cancer index |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112018009528A2 true BR112018009528A2 (pt) | 2018-11-06 |
Family
ID=58690472
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018009528A BR112018009528A2 (pt) | 2015-11-13 | 2016-11-11 | método para determinar o risco de recorrência de um câncer de mama de um sujeito, método para prever a capacidade de resposta a uma terapia de um câncer de mama de um sujeito, métodos ou tratamentos de um sujeito que tem câncer de mama que não foi tratado ou foi tratado com quimioterapia por 5 anos, métodos para recomendar o tratamento para um sujeito que tem câncer de mama, método para tratar um sujeito que tem câncer de mama |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11530448B2 (pt) |
| EP (1) | EP3374526A4 (pt) |
| BR (1) | BR112018009528A2 (pt) |
| CO (1) | CO2018004882A2 (pt) |
| IL (1) | IL259241B2 (pt) |
| MX (1) | MX2018005867A (pt) |
| WO (1) | WO2017083675A1 (pt) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108492884A (zh) * | 2018-02-08 | 2018-09-04 | 浙江大学 | 基于Logistic回归模型的胰腺神经内分泌肿瘤淋巴结转移预测系统 |
| CN108364106A (zh) * | 2018-02-27 | 2018-08-03 | 平安科技（深圳）有限公司 | 一种报销单风险预测方法、装置、终端设备及存储介质 |
| CN109272843A (zh) * | 2018-11-23 | 2019-01-25 | 神农架林区人民医院 | 用于乳腺触诊的模拟训练装置 |
| WO2022214564A1 (en) | 2021-04-06 | 2022-10-13 | Institut Curie | Methods and kits for diagnosing cancer and predicting response to treatment based on cenp-a labelling |
| WO2022235163A1 (en) * | 2021-05-07 | 2022-11-10 | Agendia N.V. | Endocrine treatment of hormone receptor positive breast cancer typed as having a low risk of recurrence |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4981783A (en) | 1986-04-16 | 1991-01-01 | Montefiore Medical Center | Method for detecting pathological conditions |
| US5545522A (en) | 1989-09-22 | 1996-08-13 | Van Gelder; Russell N. | Process for amplifying a target polynucleotide sequence using a single primer-promoter complex |
| US6482600B1 (en) | 1998-05-07 | 2002-11-19 | Lifespan Biosciences, Inc. | Breast cancer associated nucleic acid sequences and their associated proteins |
| WO2000029044A2 (en) | 1998-11-13 | 2000-05-25 | Pro Duct Health, Inc. | Devices and methods to identify ductal orifices during nipple aspiration |
| US20030064072A9 (en) | 1999-03-12 | 2003-04-03 | Rosen Craig A. | Nucleic acids, proteins and antibodies |
| US6642009B2 (en) | 1999-05-17 | 2003-11-04 | Cytyc Health Corporation | Isolated ductal fluid sample |
| AU2001229637A1 (en) | 2000-01-21 | 2001-07-31 | Thomas Jefferson University | Nipple aspirate fluid specific microarrays |
| JP2004501664A (ja) | 2000-06-30 | 2004-01-22 | ボード・オブ・リージェンツ，ザ・ユニヴァーシティ・オヴ・テキサス・システム | 標的化薬剤送達のための腫瘍組織を浸潤する細胞特異的な内部移行ペプチドの単離 |
| US6673024B2 (en) | 2000-07-28 | 2004-01-06 | Angela Soito | Cytological evaluation of breast duct epithelial cells retrieved by ductal lavage |
| AU2002211835A1 (en) | 2000-09-29 | 2002-04-08 | Clinomics Laboratories, Inc. | Oncology tissue microarrays |
| US6794141B2 (en) | 2000-12-22 | 2004-09-21 | Arcturus Bioscience, Inc. | Nucleic acid amplification |
| US7125663B2 (en) | 2001-06-13 | 2006-10-24 | Millenium Pharmaceuticals, Inc. | Genes, compositions, kits and methods for identification, assessment, prevention, and therapy of cervical cancer |
| ATE503023T1 (de) | 2001-06-18 | 2011-04-15 | Rosetta Inpharmatics Llc | Diagnose und prognose von brustkrebspatientinnen |
| US7705120B2 (en) | 2001-06-21 | 2010-04-27 | Millennium Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer |
| US7622260B2 (en) | 2001-09-05 | 2009-11-24 | The Brigham And Women's Hospital, Inc. | Diagnostic and prognostic tests |
| US20030198972A1 (en) | 2001-12-21 | 2003-10-23 | Erlander Mark G. | Grading of breast cancer |
| CA2472163C (en) | 2001-12-31 | 2012-12-18 | Dana-Farber Cancer Institute, Inc. | Psoriasin expression by breast epithelial cells |
| DK1641810T4 (en) | 2003-06-24 | 2017-07-03 | Genomic Health Inc | Predicting the likelihood of cancer recurrence |
| ES2651849T3 (es) | 2003-07-10 | 2018-01-30 | Genomic Health, Inc. | Algoritmo del perfil de expresión y test para el pronóstico del cáncer |
| BRPI0414553A (pt) | 2003-09-19 | 2006-11-07 | Arcturus Bioscience Inc | previsão do resultado de tratamento contra o cáncer de mama |
| US9856533B2 (en) | 2003-09-19 | 2018-01-02 | Biotheranostics, Inc. | Predicting breast cancer treatment outcome |
| US7504214B2 (en) | 2003-09-19 | 2009-03-17 | Biotheranostics, Inc. | Predicting outcome with tamoxifen in breast cancer |
| CN101040056A (zh) | 2004-06-04 | 2007-09-19 | 阿威亚拉德克斯股份有限公司 | Hoxb13基因对癌症的重要性 |
| AU2006246241A1 (en) | 2005-05-13 | 2006-11-16 | Universite Libre De Bruxelles | Gene-based algorithmic cancer prognosis |
| DK1899484T3 (da) | 2005-06-03 | 2015-11-23 | Biotheranostics Inc | Identifikation af tumorer og væv |
| CA2698569A1 (en) | 2007-09-06 | 2009-09-03 | Mark G. Erlander | Tumor grading and cancer prognosis |
| WO2012079059A2 (en) | 2010-12-09 | 2012-06-14 | Biotheranostics, Inc. | Post-treatment breast cancer prognosis |
| AU2012336120B2 (en) | 2011-11-08 | 2017-10-26 | Genomic Health, Inc. | Method of predicting breast cancer prognosis |
| US20150072021A1 (en) | 2013-09-09 | 2015-03-12 | British Columbia Cancer Agency Branch | Methods and Kits for Predicting Outcome and Methods and Kits for Treating Breast Cancer with Radiation Therapy |
| EP3044335B1 (en) | 2013-09-11 | 2020-09-09 | Bio Theranostics, Inc. | Predicting breast cancer recurrence |
| US10253369B2 (en) | 2014-05-29 | 2019-04-09 | Biotheranostics, Inc. | Predicting likelihood of response to combination therapy |
-
2016
- 2016-11-11 EP EP16865101.6A patent/EP3374526A4/en active Pending
- 2016-11-11 WO PCT/US2016/061568 patent/WO2017083675A1/en active Application Filing
- 2016-11-11 BR BR112018009528A patent/BR112018009528A2/pt active Search and Examination
- 2016-11-11 IL IL259241A patent/IL259241B2/en unknown
- 2016-11-11 US US15/349,915 patent/US11530448B2/en active Active
- 2016-11-11 MX MX2018005867A patent/MX2018005867A/es unknown
-
2018
- 2018-05-08 CO CONC2018/0004882A patent/CO2018004882A2/es unknown
-
2022
- 2022-11-18 US US18/056,967 patent/US20230083179A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2018005867A (es) | 2018-09-21 |
| US11530448B2 (en) | 2022-12-20 |
| US20170137891A1 (en) | 2017-05-18 |
| IL259241B2 (en) | 2024-04-01 |
| EP3374526A4 (en) | 2019-09-11 |
| US20230083179A1 (en) | 2023-03-16 |
| EP3374526A1 (en) | 2018-09-19 |
| WO2017083675A1 (en) | 2017-05-18 |
| CO2018004882A2 (es) | 2018-08-10 |
| IL259241B1 (en) | 2023-12-01 |
| IL259241A (en) | 2018-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018009528A2 (pt) | método para determinar o risco de recorrência de um câncer de mama de um sujeito, método para prever a capacidade de resposta a uma terapia de um câncer de mama de um sujeito, métodos ou tratamentos de um sujeito que tem câncer de mama que não foi tratado ou foi tratado com quimioterapia por 5 anos, métodos para recomendar o tratamento para um sujeito que tem câncer de mama, método para tratar um sujeito que tem câncer de mama | |
| BR112018067368A2 (pt) | terapia de combinação com anticorpos anti-cd73 | |
| MX2023002251A (es) | Antagonistas de union al eje pd-l1 y usos de los mismos para el tratamiento de cancer. | |
| MX2022006075A (es) | Antagonistas de union a pd-l1 y usos de los mismos para el tratamiento de cancer. | |
| MX2018010261A (es) | Inhibidores de idh1 para el tratamiento de neoplasias malignas hematologicas y tumores solidos. | |
| WO2017096309A8 (en) | Methods of treatment of malignancies | |
| BR112018013853A2 (pt) | composições e métodos relacionados a sistemas celulares terapêuticos multimodais para indicações de câncer | |
| BR112018077136A2 (pt) | composto, e, métodos para tratar um distúrbio associado com proliferação celular anormal e para reduzir o efeito de quimioterapia em células saudáveis. | |
| MX2017013178A (es) | Terapia de combinacion para cancer. | |
| BR112017021312A2 (pt) | tratamento de câncer de pulmão com inibidores de glutaminase | |
| BR112018008503A2 (pt) | método para tratar câncer de pulmão de células pequenas, método para tratar um sujeito, método para selecionar um sujeito com câncer | |
| MX2022008868A (es) | Tratamiento del cancer con tg02. | |
| EA201792509A1 (ru) | Лечение рака | |
| BR112018007656A2 (pt) | terapia de combinação para tratamento de doenças malignas | |
| MX2021013938A (es) | Metodos y composiciones para prediccion de eficacia terapeutica de tratamientos contra el cancer y prognosis del cancer. | |
| BR112016024789A2 (pt) | métodos de tratamento de câncer de mama em fase inicial com trastuzumabe-mcc-dm1 e pertuzumabe | |
| BR112017020002A2 (pt) | Combinação de inibidor de hdac e anticorpo anti- pd-1 para o tratamento de câncer | |
| BR112015033053A2 (pt) | método de tratamento de câncer em um sujeito, método de estimulação do sistema imune em um sujeito, método de aumentar a distribuição de um agente anticâncer a uma célula tumoral, composição, e kit | |
| MX2015007185A (es) | Uso de eribulina en el tratamiento de cancer de pecho. | |
| BR112016025040A2 (pt) | métodos para determinar a expressão de biomarcador mit, para tratar câncer, para identificar um indivíduo com câncer, para predizer se um indivíduo com câncer tem mais ou menos probabilidade de responder efetivamente ao tratamento, para inibir a proliferação de uma célula e para tratar nccrcc em um indivíduo | |
| MX2020010269A (es) | Un anticuerpo anti-il-23p 19 (mirikizumab) para usarse en el tratamiento de la colitis ulcerosa. | |
| MX2016015378A (es) | Uso de eribulina en el tratamiento de cancer. | |
| EA201890868A1 (ru) | Бактерии с ослабленной вирулентностью для лечения злокачественных солидных опухолей | |
| BR112016025333A2 (pt) | agente, produto e uso | |
| BR112019008241A2 (pt) | tratamento do prurigo nodular |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] |